NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




Cancer Control Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Any Site

DCP-001 -"Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)"

CANCER TYPE: Any Site
RESEARCH BASE: NCI
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
Additional Consent Form: VIEW CONSENT FORM 2
Additional Consent Form: VIEW CONSENT FORM 3
BRIEF DESCRIPTION

Screening tool used to collect expanded demographic and clinical data (e.g., SES, co-morbidities, method of diagnosis) across the NCORP network to help identify and best characterize patients that are screened but not enrolled in cancer control studies.






URCC 13059 - "A GERIATRIC ASSESSMENT INTERVENTION FOR PATIENTS AGED 70 AND OVER RECEIVING CHEMOTHERAPY FOR ADVANCED CANCER: REDUCING CHEMOTHERAPY TOXICITY IN OLDER ADULTS (GAP 70+)"

CANCER TYPE: Any Site
RESEARCH BASE: URCC 13059
NCT NUMBER: 02054741
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
Additional Consent Form: VIEW CONSENT FORM 2
BRIEF DESCRIPTION

Any solid tumor, Stg III-IV, age >=70, planned 1st-line chemo; Eval of Geriatric Asmt & recommendations in reducing chemo toxicity (Drs must sign a consent for their own study participation. Site may enroll pts after 1 investigator has been enrolled for the site.)






Brain/CNS

CTSU Alliance A221101 - "A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil;) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma"

CANCER TYPE: Brain/CNS
RESEARCH BASE: CTSU Alliance A221101
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Glioma (high-grade), clinically stable post RT & chemo, >=6 on worst fatigue scale; Armodafinil (2 dosage arms) vs. placebo to reduce cancer-related fatigue






Breast

Alliance A011104 - "EFFECT OF PREOPERATIVE BREAST MRI ON SURGICAL OUTCOMES, COSTS AND QUALITY OF LIFE OF WOMEN WITH BREAST CANCER"

CANCER TYPE: Breast
RESEARCH BASE: Alliance
NCT NUMBER: NCT01805076
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Breast ca, stage I-II, elig for BCT, compare local recurrence rates following BCT using preop staging w/mammography + MRI vs mammography only






CTSU Alliance A211201 - "Change in Mammographic Density with Metformin Use: A Companion Study to NCIC MA.32"

CANCER TYPE: Breast
RESEARCH BASE: CTSU Alliance 211201
NCT NUMBER:
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Current or prior enrollment on CTSU NCIC MA.32, hormone receptor (-), breast density >25%; Eval of mammographic density change w/Metformin use






WF 98213 - "Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT)"

CANCER TYPE: Breast
RESEARCH BASE: Wake Forest
NCT NUMBER: NCT01988571
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Cancer control, Stage I-III breast ca treated with an anthracycline, atorvastatin vs placebo for possible prevention of left ventricular dysfunction






GI

SWOG S0820 - "A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)".

CANCER TYPE: GI
RESEARCH BASE: SWOG S0820
NCT NUMBER: 01349881
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Colorectal, prior Stg 0-III w/resection alone or in combination with radiation or chemotherapy, NED, Placebo-controlled Eflornithine & Sulindac to prevent high-risk adenoma & 2nd prim recurrence






Lung

NRG CC003 - "RANDOMIZED PHASE II/III TRIAL OF PROPHYLACTIC CRANIAL IRRADIATION WITH OR WITHOUT HIPPOCAMPAL AVOIDANCE FOR SMALL CELL LUNG CANCER"

CANCER TYPE: Lung
RESEARCH BASE: NRG
NCT NUMBER: NCT02635009
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

PCI w/wo hippocampal avoidance, small cell lung cancer, neurocognitive assessment






MDS

NHLBI-MDS "The National Myelodysplastic Syndromes (MDS) Study"

CANCER TYPE: MDS
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT02775383
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Collect clinical data and biological specimens in order to develop databases to support MDS studies.









  © 2013-2017 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA